---
layout: default
title: Iron
parent: 僅模型預測 (L5)
nav_order: 420
evidence_level: L5
indication_count: 6
---

# Iron
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Iron (DB01592): A Low-Confidence Signal for Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia

## One-Sentence Summary

Iron (DrugBank DB01592) has no documented original indication in this evidence pack, and it is not currently marketed in Canada (0 DINs on file).
The TxGNN model predicts a possible link to **Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia**,
but **zero clinical trials** and **zero publications** currently support this specific disease pairing.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not on file — no approved indication text is recorded for this DrugBank entry |
| Predicted New Indication | Vitamin B12- and folate-independent constitutional megaloblastic anemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available for this drug entry, so the pharmacological rationale below relies on the disease definition itself rather than a confirmed MOA.

This predicted indication is, by clinical definition, a megaloblastic anemia that is *independent* of vitamin B12 and folate status — it is typically caused by mitochondrial metabolic defects or inherited nucleotide-synthesis gene mutations (e.g., TRMA-type syndromes), not by iron deficiency or microcytic anemia pathophysiology. There is no established biochemical pathway through which iron supplementation would correct this disorder.

The evidence pack's own repurposing rationale flags this directly: the high TxGNN score likely reflects co-occurrence of "anemia"-related nodes in the knowledge graph rather than a genuine mechanistic relationship. Absent any supporting clinical or preclinical data, this candidate should be treated as a graph-artifact hypothesis rather than a biologically grounded repurposing signal.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Canada Market Information

Iron (DB01592) has no licenses on file in this evidence pack — market status is "Not Marketed" with 0 total DINs recorded, so no product-level authorization table can be generated at this time.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- No clinical trials or literature currently link iron to this specific megaloblastic anemia subtype, and the evidence pack's own rationale suggests the TxGNN score likely reflects spurious node co-occurrence rather than a real mechanistic relationship.
- A blocking data gap (missing Health Canada/label warnings and contraindications) means this candidate cannot even clear the initial safety screening stage.

**To proceed, the following is needed:**
- Health Canada product monograph — warnings, precautions, and contraindications (currently a Blocking data gap)
- Confirmed mechanism of action data from DrugBank (currently a High-severity data gap)
- Any preclinical or case-level evidence directly connecting iron therapy to this megaloblastic anemia subtype
- A documented original indication for this drug entry, to establish a baseline for comparison

**Note for reviewers:** within this same evidence pack, two other candidates for Iron show materially stronger support and may warrant priority review instead — *Plummer-Vinson syndrome* (L3, 19 literature citations, "Proceed with Guardrails") and *Vitamin Deficiency Disorder* (L2, extensive clinical-trial and literature support, "Proceed with Guardrails").
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

